Literature DB >> 19649712

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Radojka M Savic1, Mats O Karlsson.   

Abstract

Empirical Bayes ("post hoc") estimates (EBEs) of etas provide modelers with diagnostics: the EBEs themselves, individual prediction (IPRED), and residual errors (individual weighted residual (IWRES)). When data are uninformative at the individual level, the EBE distribution will shrink towards zero (eta-shrinkage, quantified as 1-SD(eta (EBE))/omega), IPREDs towards the corresponding observations, and IWRES towards zero (epsilon-shrinkage, quantified as 1-SD(IWRES)). These diagnostics are widely used in pharmacokinetic (PK) pharmacodynamic (PD) modeling; we investigate here their usefulness in the presence of shrinkage. Datasets were simulated from a range of PK PD models, EBEs estimated in non-linear mixed effects modeling based on the true or a misspecified model, and desired diagnostics evaluated both qualitatively and quantitatively. Identified consequences of eta-shrinkage on EBE-based model diagnostics include non-normal and/or asymmetric distribution of EBEs with their mean values ("ETABAR") significantly different from zero, even for a correctly specified model; EBE-EBE correlations and covariate relationships may be masked, falsely induced, or the shape of the true relationship distorted. Consequences of epsilon-shrinkage included low power of IPRED and IWRES to diagnose structural and residual error model misspecification, respectively. EBE-based diagnostics should be interpreted with caution whenever substantial eta- or epsilon-shrinkage exists (usually greater than 20% to 30%). Reporting the magnitude of eta- and epsilon-shrinkage will facilitate the informed use and interpretation of EBE-based diagnostics.

Entities:  

Mesh:

Year:  2009        PMID: 19649712      PMCID: PMC2758126          DOI: 10.1208/s12248-009-9133-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  34 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

Review 2.  A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective.

Authors:  Janet R Wade; Monica Edholm; Tomas Salmonson
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Evaluation of the nonparametric estimation method in NONMEM VI.

Authors:  Radojka M Savic; Maria C Kjellsson; Mats O Karlsson
Journal:  Eur J Pharm Sci       Date:  2008-12-30       Impact factor: 4.384

4.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

5.  Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.

Authors:  I F Trocóniz; T H Naukkarinen; H M Ruottinen; U K Rinne; A Gordin; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  1998-07       Impact factor: 6.875

6.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

7.  Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Authors:  Marie Cullberg; Ulf G Eriksson; Karin Wåhlander; Henry Eriksson; Sam Schulman; Mats O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2005-04       Impact factor: 6.875

8.  Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.

Authors:  L Brynne; J L McNay; H G Schaefer; K Swedberg; C G Wiltse; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

9.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

10.  Application of population pharmacokinetics to cladribine.

Authors:  Synnöve Lindemalm; Radojka M Savic; Mats O Karlsson; Gunnar Juliusson; Jan Liliemark; Freidoun Albertioni
Journal:  BMC Pharmacol       Date:  2005-03-09
View more
  265 in total

1.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

2.  Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

Authors:  B D Lacroix; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

3.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

4.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

5.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

6.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

7.  Visual Predictive Check in Models with Time-Varying Input Function.

Authors:  Anna Largajolli; Alessandra Bertoldo; Marco Campioni; Claudio Cobelli
Journal:  AAPS J       Date:  2015-08-12       Impact factor: 4.009

8.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

9.  Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach.

Authors:  Valentina Topić Vučenović; Zvezdana Rajkovača; Dijana Jelić; Dragi Stanimirović; Goran Vuleta; Branislava Miljković; Katarina Vučićević
Journal:  Eur J Clin Pharmacol       Date:  2018-05-13       Impact factor: 2.953

10.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.